| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID6328: Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | osimertinib (Tagrisso®) |
| Formulation | 40 mg and 80 mg film-coated tablets |
| Reference number | 5349 |
| Indication | Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer |
| Company | AstraZeneca UK Limited |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/04/2025 |
| NICE guidance | |